Researchers studied 338 adults with obesity or overweight who did not have diabetes
After you complete your third dosage in a given month, you can fill out your refill intake in your portal
This product is supplied solely for laboratory investigation and is not approved for human use, clinical applications, or human consumption
In this study, nearly a third of patients lost 25% or more of their starting weight on the higher dose of semaglutide, compared with only 15% who lost that amount on 2.4 mg and none on the placebo
Notably, tirzepatide is characterised in the literature as an imbalanced or biased dual agonist: its affinity for the GIP receptor is comparable to native GIP, while its affinity for the GLP-1 receptor is roughly 18- to 20-fold weaker than native GLP-1
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data